Literature DB >> 28049380

Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-α production in SLE patients.

Sahar Mortezagholi1, Zohreh Babaloo1, Parisa Rahimzadeh2, Haideh Namdari3, Mojgan Ghaedi2, Farhad Gharibdoost4, Reza Mirzaei5, Katayoon Bidad6, Eisa Salehi5.   

Abstract

CONTEXT: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoreactive antibodies. Recent findings revealed the importance of innate immune responses, especially Toll-like receptors (TLRs) in the pathogenesis of SLE.
OBJECTIVE: In this study, the level of TLR9 expression on peripheral blood mononuclear cells (PBMCs) was analyzed. The levels of produced IFN-α were also measured in supernatant of PBMCs from SLE patients and healthy controls after stimulation with CpG ODN2216 which is a plasmocytoid dendritic cell (pDC)-specific TLR9 ligand.
MATERIALS AND METHODS: TLR9 expression was analyzed by real-time polymerase chain reaction (PCR) and flow cytometry in 35 SLE patients and 38 healthy controls and IFN-α concentration was measured in supernatants using enzyme-linked immunosorbent assay (ELISA).
RESULTS: The results showed that the TLR9 expression in the mRNA and the protein level was significantly higher in PBMCs from SLE patients. However, IFN-α concentration in patients and controls significantly increased in response to CpG stimulation but this increase was significantly higher in healthy controls compared with SLE patients. Our results do not show any association between taking hydroxychloroquine and reduction in IFN-α production in SLE patients. DISCUSSION AND
CONCLUSIONS: Regarding the findings of the study, there is the possibility that TLR9 has played a role in SLE pathogenesis, and consequently it implies that TLRs can be considered to be the therapeutic targets for systemic autoimmunity. We may conclude that PBMCs in patients are functionally impaired in response to TLR ligation via innate response stimulating pathogen-associated molecular patterns (PAMPs).

Entities:  

Keywords:  Antinuclear antibody; CpG oligodeoxynucleotide; Toll-like receptor 9; interferon-I; systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 28049380     DOI: 10.1080/08923973.2016.1263859

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  11 in total

1.  Different interleukin-17-secreting Toll-like receptor+ T-cell subsets are associated with disease activity in multiple sclerosis.

Authors:  Thais B Ferreira; Joana Hygino; Ana Cristina Wing; Taissa M Kasahara; Priscila M Sacramento; Solange Camargo; Fernanda Rueda; Soniza V Alves-Leon; Regina Alvarenga; Claudia Cristina Vasconcelos; Anshu Agrawal; Sudhir Gupta; Cleonice A M Bento
Journal:  Immunology       Date:  2017-12-26       Impact factor: 7.397

2.  17β-Estradiol and 17α-Ethinyl Estradiol Exhibit Immunologic and Epigenetic Regulatory Effects in NZB/WF1 Female Mice.

Authors:  Rujuan Dai; Michael R Edwards; Bettina Heid; S Ansar Ahmed
Journal:  Endocrinology       Date:  2019-01-01       Impact factor: 4.736

3.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

Review 4.  Our Environment Shapes Us: The Importance of Environment and Sex Differences in Regulation of Autoantibody Production.

Authors:  Michael Edwards; Rujuan Dai; S Ansar Ahmed
Journal:  Front Immunol       Date:  2018-03-08       Impact factor: 7.561

Review 5.  Below the surface: The inner lives of TLR4 and TLR9.

Authors:  Laura Marongiu; Laura Gornati; Irene Artuso; Ivan Zanoni; Francesca Granucci
Journal:  J Leukoc Biol       Date:  2019-03-22       Impact factor: 4.962

6.  Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells.

Authors:  Duaa Babaer; Suneetha Amara; Brenda S McAdory; Owen Johnson; Elbert L Myles; Roy Zent; Jeffrey C Rathmell; Venkataswarup Tiriveedhi
Journal:  Cancers (Basel)       Date:  2019-05-14       Impact factor: 6.639

7.  Low-dose 17α-ethinyl estradiol (EE) exposure exacerbates lupus renal disease and modulates immune responses to TLR7/9 agonists in genetically autoimmune-prone mice.

Authors:  Michael R Edwards; Rujuan Dai; Bettina Heid; Catharine Cowan; Stephen R Werre; Thomas Cecere; S Ansar Ahmed
Journal:  Sci Rep       Date:  2020-03-23       Impact factor: 4.379

8.  Immunogenetic Relationship of HLA-G 14 bp Insertion/Deletion Polymorphism and Toll-Like Receptor 9 with Systemic Lupus Erythematosus in Egyptian Patients: A Case-Control Study.

Authors:  Shrouk A Mohammed; Laila M Al Kady; Ghada S Boghdadi; Ghada A Dawa; Marian A Gerges; Maher A El Shafai
Journal:  Int J Gen Med       Date:  2022-01-18

9.  Impaired Innate Immunity in Pediatric Patients Type 1 Diabetes-Focus on Toll-like Receptors Expression.

Authors:  Katarzyna Kurianowicz; Maria Klatka; Agnieszka Polak; Anna Hymos; Dominika Bębnowska; Martyna Podgajna; Rafał Hrynkiewicz; Olga Sierawska; Paulina Niedźwiedzka-Rystwej
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

10.  Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?

Authors:  Erika Aurora Martínez-García; Maria Guadalupe Zavala-Cerna; Andrea Verónica Lujano-Benítez; Pedro Ernesto Sánchez-Hernández; Beatriz Teresita Martín-Márquez; Flavio Sandoval-García; Mónica Vázquez-Del Mercado
Journal:  Front Immunol       Date:  2018-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.